找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T

[复制链接]
查看: 18151|回复: 54
发表于 2025-3-21 16:11:48 | 显示全部楼层 |阅读模式
期刊全称Biosimilars for Cancer Treatment
期刊简称A Promising Approach
影响因子2023Shvetank Bhatt,Harish Dureja,Kamal Dua
视频video
发行地址Covers the recent clinical trials of biosimilars for cancer treatment.Provides information about the analysis of regulatory complexities in cancer care.Explores the role of biosimilars in improving th
图书封面Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T
影响因子.The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers...It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment..
Pindex Book 2024
The information of publication is updating

书目名称Biosimilars for Cancer Treatment影响因子(影响力)




书目名称Biosimilars for Cancer Treatment影响因子(影响力)学科排名




书目名称Biosimilars for Cancer Treatment网络公开度




书目名称Biosimilars for Cancer Treatment网络公开度学科排名




书目名称Biosimilars for Cancer Treatment被引频次




书目名称Biosimilars for Cancer Treatment被引频次学科排名




书目名称Biosimilars for Cancer Treatment年度引用




书目名称Biosimilars for Cancer Treatment年度引用学科排名




书目名称Biosimilars for Cancer Treatment读者反馈




书目名称Biosimilars for Cancer Treatment读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:48:20 | 显示全部楼层
发表于 2025-3-22 00:51:31 | 显示全部楼层
发表于 2025-3-22 07:58:13 | 显示全部楼层
发表于 2025-3-22 10:20:44 | 显示全部楼层
发表于 2025-3-22 15:49:15 | 显示全部楼层
发表于 2025-3-22 19:01:48 | 显示全部楼层
发表于 2025-3-23 00:21:12 | 显示全部楼层
U. M. Lütolf,P. Huguenin,C. Glanzmann for use in both the disease itself and as supportive drugs for cancer patients. The reduction in the treatment cost using trastuzumab biosimilars is approximately 20–30% lower in comparison to the costs using the reference product. The supportive drugs include haematopoietic growth factors like ery
发表于 2025-3-23 01:35:18 | 显示全部楼层
发表于 2025-3-23 09:02:06 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-27 04:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表